No Prescription |
 |
 | ||
|
Isordil Generic isosorbide Dinitrate |
|
| ||
No Prescription » Prescription Drugs 9 » Isordil Generic isosorbide Dinitrate Isosorbide dinitrate is used to prevent chest pain (angina) in patients with a certain heart condition (coronary artery disease). This medication belongs to a class of drugs known as nitrates. It works by relaxing and widening blood vessels so blood can flow more easily to the heart.This medication will not relieve chest pain once it occurs. It is also not intended to be taken just before physical activities (such as exercise sexual activity) to prevent chest pain. Other medications may be needed in these situations. Consult your doctor for more details. Buy Isordil Generic isosorbide Dinitrate and other Prescription Drugs 9 products online at Medstore. Buy Online at Medstore - Click Here!
About Isordil Generic isosorbide Dinitrate: Product Type: Prescription Drugs 9 Isordil ( Generic isosorbide Dinitrate ) Isordil (Generic isosorbide Dinitrate) Generic isosorbide Dinitrate 10mg 200 Tablets 10mg 100 Tablets 10mg 50 Tablets 5mg 50 Tablets 5mg 100 Tablets 5mg 200 Tablets Generic isosorbide Dinitrate Isordil
View more Prescription Drugs 9 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
